SPEAKERS

Dr. Ayca Yildiz-Pekoz has obtained, in 2006, her co-accredited Doctoral Degree from Istanbul University and the University of Cardiff of UK, where she has worked in the lab of Professor Mark Gumbleton. She belongs to the first cohort of EU’s prestigious Marie Curie Scholarship in EuroPhD program. She focuses on nasal and pulmonary drug targeting, micro/nano carrier systems as localized therapies, pharmaceutical applications of cell culture studies, Vitamin C transport mechanisms via/into lung, and anti-cancer buccal delivery technologies. She holds 8 patents, 6 of which are COVID-19 related.

Dr. Ayca Yildiz-Pekoz has 10 years of experience in the regulatory bodies and in private consulting. Dr. Yildiz-Pekoz is a member of the Aerosol Society, of the local chapter of the Controlled Release Society as well as Pharmaceutical Researchers Society of Turkey. She is the Founding President of the Pulmonary Drug Delivery Researchers’ Association, a new and growing network of pulmonary scientists across European universities. She is the co-director of the yearly Pulmonary Drug Delivery Workshop series, the second largest conference of its kind in Europe.

​

​

​

​

​

Carsten is Professor in Pharmaceutics and Biopharmaceutics and Fellow at Trinity College Dublin. His research is focused on lung drug disposition and pulmonary epithelial transport. Moreover, he is interested in molecular origins of airways disease. Carsten has edited 1 book and (co-) authored 110 peer-reviewed publications and over 250 abstracts. He is the recipient of honours and awards from German Pharmaceutical Society (DPhG), American Physiological Society and Galenus Foundation. Carsten serves as Associate Editor of Journal of Aerosol Medicine and Pulmonary Drug Delivery and Section Editor of European Journal of Pharmaceuticals Sciences and is a member of the Editorial Boards of European Journal of Pharmaceutics and Biopharmaceutics, Journal of Pharmaceutical Sciences, Pharmaceutics, and Pharmaceutical Research.In 2013, he organised the first PDD Workshop in Dublin. 

​

Philippe is a Pharma Entrepreneur with a track record of driving business growth within the drug delivery technology sector. Philippe is an inhaled drug delivery key

opinion leader and expert with a global reputation. Philippe has an enviable track record in developing pMDI, DPI, Nebules, Nasal and Soft Mist inhalers. Philippe has founded a number of successful ventures in Europe and Asia. Philippe is currently Chief Business officer and Founder of Merxin Ltd and CEO of Anthocan Ltd, companies dedicated to improving and creating new inhaled therapies. His LinkedIn blog Inhaled Drug Delivery Specialist is the largest group dedicated to that

field of research.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Federico Lavorini is Professor of Respiratory Medicine at the Department of Clinical and Experimental Medicine,

University of Florence Italy; he is also Head of the Respiratory and Critical Care Unit at the Careggi University Hospital, Florence, Italy. He qualified in Medicine at the University of Florence (1991), has the Specialist Certification in Respiratory Medicine (1996), and he also undertook a Ph.D. board certified in Applied Pathophysiology (2000). His research interests are control of breathing in health and disease, cough and inhalation devices for delivering aerosol medications. At the present, he is member of the Aerosol Drug Management

Improvement Team (ADMIT), an european consortium of respiratory physician with special interests in aerosol

medicine. He is also member of the Respiratory Effectiveness Group (REG), an investigator-led, social enterprise research initiatve. Federico Lavorini is Co-Chair of the European Respiratory Society /International Society of Aerosol in Medicine Taskforce on inhaled therapy and devices of the. He is also Chair of the Italian Respiratory Society (SIP) Taskforce on aerosol delivery systems. Federico Lavorini is Associate Editor and Review Editor of the Clinical Respiratory Journal, Respiratory Physiology and Pathophysiology, Frontiers in Physiology. He acts as Board member of the International Society for Aerosol in Medicine (ISAM), of the Journal of Aerosol Medicine and Pulmonary Drug Delivery, and of the BioMed Research International, Pulmonology.

​

Dr. Gur Jai Pal Singh is a Senior VP and has headed the Cipla Respiratory Centre of Excellence since 2013. A number of orally inhaled products have been developed, filed and approved under his leadership. Earlier, he had spent many years of his professional life at the US FDA, where he was also the designated expert on respiratory drug products in the Office of Generic Drugs.

Dr Singh strongly believes in continued innovations relevant to reduction of product development expenditures, particularly through explorations for cost-effective alternatives to the resource-intensive clinical studies to support bioequivalence (BE) of drugs - for which the systemic bioavailability (BA) may is not directly related to drug delivery at the relevant local site (s) of action. While at the FDA, Dr. Singh played a lead role in establishing BE of nasal solution sprays and aerosols and, also, spearheaded the effort to provide allowance for

BE documentation of an inhaled suspension based solely on in vitro testing. Numerous ANDAs have been approved utilizing these approaches. Application of PK and PD modelling to resolution of complex BE issue is one of Dr. Singh’s key interests. At the FDA, he spearheaded application of PD models in statistical evaluation

of BE of inhalation aerosols. In addition, he explored and introduced population modelling that determines the doses used in the BE study of certain topical products. These approaches have been used in the development and FDA approval of a number of products.

Dr. Singh continues his pursuit of for BE alternatives to the conventional clinical end point studies. Since 2015, he has focused on the evaluation and application of in silico techniques in the development and application of BE of inhalation aerosols. His development program

included, but not limited to, clinically relevant in vitro performance testing, in silico determination of lung deposition, plume evaporation kinetics, mechanistic PBPK modelling and computational fluid dynamics. This journey has provided valuable insights about relevance and limitations of all these approaches in successful determination of BE of inhalation aerosols.

Dr. Singh also commands international recognition and respect for his expertise in this filed. He has participated by invitation in a number of expert panels debating regulatory and development issues related to respiratory drug products, given invited lectures at lead international forums such as RDD, ISAM and IPAC-RS conferences. He chaired symposiaand co-chaired committees for organization of several international conferences.

​

Irene Rossi is the Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Pharma Company (UK) where she leads a group focused on formulation development of OINDP comprising both small and large molecules.

Having achieved a Master in Pharmaceutical Chemistry and Technology in 2014, Irene spent 6 years

at the University of Parma (IT) working on formulation development of nasal and inhalationproducts, particularly focusing on particle engineering. She obtained her PhD in Drugs, Biomolecules and Health Products in 2019. In the same year she joined Nanopharm (UK) as Senior Scientist and, successively, as Laboratory Supervisor and Principal Scientist.

During her PhD, she spent 6 months at the University of New Mexico, College of Pharmacy (NM, USA), where she acquired competences on in vitro cell studies and in vivo animal studies. She was selected as finalist for The Pat Burnell New Investigator Award at Drug Delivery to the Lungs in 2017 with a study on pulmonary vaccination against Human Papillomavirus and, again, in 2018

with a project on the development of spray dried polymeric nano-embedded microparticles for

tuberculosis and not tuberculous mycobacterial infections.

Up to date, Irene has published and submitted 7 original papers, 4 patent applications and she has

presented her work at over 20 international conferences.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Jeremy Paulen is the Director Business Development Allergic Rhinitis in Aptar Pharma, leading the worldwide strategy of the range.

Jeremy holds a Master degree in Pharmaceutical Marketing Industry from Paris; he works in the Pharma Industry for the last 10 Years with past experiences in General Management, Innovation, Marketing, and Project management, carried out in France and various Markets.
Well experienced in change management, Jeremy is passionate about serving patients and consumers with best treatments and services, and at the same time caring for our planet 

Dr. Bing V. Li serves as the Associate Director for Science for Office of Bioequivalence within the Office of Generic Drugs at CDER/FDA. In this role, she provides scientific leadership and expertise for the assessment of the bioequivalence studies submitted by pharmaceutical industry through Abbreviated New Drug Applications (ANDAs) and oversees the scientific programs including guidance development and implementation in Office of Bioequivalence.  Dr. Li is an Expert Pharmacologist at the FDA in the area of bioequivalence of aerosolized drug products. Prior to joining FDA in 2004, she was a Research Investigator at Bristol-Myer-Squibb where her responsibilities included formulation identification, development and optimization for oral solid dosage form formulations. Dr. Bing V. Li received her Ph.D. in Pharmaceutical Sciences from University of Wisconsin at Madison in 2001, and a bachelor’s degree in Medicinal Chemistry in 1990 in Beijing University, China.

Dr. Hochhaus received his Ph.D. in 1984 at the Institute of Pharmaceutical Chemistry, Westf. Wilhems University (Münster, Germany). He completed a postdoctoral

fellowship at the University of California-San Francisco and subsequently joined the University of Florida’s College of Pharmacy as an Assistant Professor in 1987, where he continues to serve today as a Professor of Pharmaceutics. Dr. Hochhaus’ research is interested in evaluating inhalation drugs through in vitro and pharmacokinetic/dynamic approaches. He collaborates with regulatory authorities to improve methodology for

drug approval of generic inhalation drugs. 

Dr. Hochhaus is a Fellow of AAPS and the American College of Clinical Pharmacology (ACCP). In 1998, he was recipient of the young investigator award of the German Airway and Lung Research Society and received ACCP’s Tanabe Young Investigator Award. He was awarded the University of Florida Foundation Research Professorship in 2015-2018; 2019-2022, American College of Clinical Pharmacology’s Bristol-Myers Squibb Mentorship in Clinical Pharmacology Award (2019) and is Honorary Regent of ACCP. In 2022, he received the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery. He has published more than 240 research papers.

​

Berrak Çağlayan Yeğen, M.D.

has graduated in 1983 from Ege University Medical Faculty in İzmir, and after her obligatory service in Eskişehir, she has started training in Physiology at Marmara University Medical Faculty, and since 1992 she is working as the Professor of Physiology at the same deparment. She is the member of Association for Evaluation and Accreditation of Medical Education Programs in Turkey and abroad. Her major interests in research are gastrointestinal motility, neural and hormonal mechanisms controlling gastric emptying and gastric acid secretion and the pathophysiology of inflammatory processes.  She has received Eczacıbaşıbaşı Scientific Research Award, Ibrahim Ethem Ulagay Toxicology Award, Istanbul Medical Doctors’ Chamber Medical Science Award and Sedat Simavi Health Sciences Award. She is the member of  The Science Academy.

​

​

​

​

​

PhD. in Endocrinology and Metabolic Diseases, University of Gent, Belgium1984 Board Certification in Internal Medicine 1987 

Academic Career

1.Research Director National Fund for Scientific Research

2.Professor of Endocrinology University of Gent

3.Head of Metabolic Diseases/Diabètes, Lipid, Eating Disorders and Nutrition at University of Gent and of the University Hospital

4.Research at Dept of Human Nutrition University of Wageningen

5.Research at Dept of Endocrinoloy Southwestern Medical School Dallas

6.Visiting Professor Kings College London

​

Clinical Research Career

1.Director International Operations BARC central lab

2.Vice President Asia Pacific ICON Clinical Research Research

3.Director National Healtcare Group Singapore,

4.Director CTERU Singapore, Director CTRG, Director CTU NUH Singapore, 

5.Vice President Asia Pacific Life Sciences SGS

6.Founder and owner Aesculape CRO 2010-current

​

Honors

1.Nutricia bursar, NWO bursar, NATO bursar

2.Fulbright fellow

3.Honorary Fellow Faculty Pharmaceutical Medicine Royal College of Physicians UK

4.Associate Editor Frontiers in Pharmacology-Pharmaceutical Medicine

5.Member Editorial Board Int J Pharmaceutical Med​

​

Wilbur de Kruijf is the founder and general manager of Thaerapy BV, a small specialty pharma company in the Netherlands. Thaerapy creates drug device combination products for inhalation. Thaerapy’s first product, for pulmonary hypertension, is based on Resyca’s pre-filled syringe inhaler, which is based on Medspray’s soft mist nozzle technology. 

Wilbur (born in 1971) has a background in Industrial Design Engineering (M.Sc. Design Engineering 1995, M.Sc. Advanced Industrial Design Engineering 1997, Delft University of Technology) with further specialization in medical device development (acc. ISO 13485), design for six sigma and user-centered design. Before working on soft mist inhalers with  Medspray in 2006, Wilbur worked almost 10 years for a Dutch design consultancy firm named Indes, winning several international design and usability awards for homecare & rehab products and hospital equipment. Wilbur is the secretary of the Dutch medical aerosol scientist network ‘MAD Foundation’.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Dr Ronan MacLoughlin, PhD, MBS is currently Director of R&D, Science and Emerging Technologies in Aerogen Limited. Dr MacLoughlin has more than 20 years’ experience in Respiratory Drug Delivery with several nebuliser, and accessory product launches over that time. He has responsibility for new product development, establishing and exploiting the science underpinning respiratory drug delivery and identifying new and potentially disruptive emerging technologies. To this end, he has developed multiple technologies and products with several patents granted and pending, that cover the range of drug, device, drug/device combination products, patient interventions and patient interfaces. Of note, this includes the world’s first fit for purpose mass vaccination by inhalation delivery system, currently in use with Convidicia Air, the inhaled COVID-19 vaccine.

Dr MacLoughlin currently serves as chair of the Industry Representative Group in CURAM, the Science Foundation Ireland center for the development the next generation of smart medical devices, and sits on the board, (previously chair) of the Medical and Engineering Technologies Center (MET), the Enterprise Ireland Technology Gateway. Additionally, he is currently chair of the Paediatric and Cystic Fibrosis working group within the International Society for Aerosols in Medicine (ISAM). He sits on the board of LEP Biomedical, a preclinical company focused on the development of novel implantable drug delivery systems for the treatment of glaucoma and other ophthalmic conditions. 

Finally, Dr MacLoughlin holds the position of adjunct Associate Professor in Trinity College Dublin (School of Pharmacy and Pharmaceutical Sciences), and Senior Honorary lecturer in the Royal College of Surgeons, Ireland (School of Pharmacy & Biomolecular Sciences).  

​

​

Sanjeeva is a consultant in pharmaceutical medicine and regulation. He graduated from the Royal Free Hospital School of Medicine in London, is a member of the Royal College of Physicians, and has a masters degree in Respiratory Medicine from Imperial College, London. Over the past 23 years he has held a number of senior roles in clinical development in the pharmaceutical industry, has worked in both biotech and pharma settings, and has been centrally involved in the development and approval of both proprietary and generic inhaled drugs. Additionally, he spent approximately 5 years at the UK medicines agency (the MHRA), thus also under the auspices of EMA, within the division licensing new respiratory medicines and providing scientific advice on such developments. He currently works as an independent consultant specialising in respiratory drug development.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Ulf Krueger, CEO and founder of PULMOTREE. His experience in life sciences and especially in managing projects, programs and portfolios is the basis of Pulmotree’s  business. He also brings his broad industry knowledge of strategic development, product management, R&D and industrialization of inhaled drug delivery products.

In his former position as Director – Fox Nebulizer Programs at Vectura, he held responsibility for the entire sector of the proprietary mesh nebulizers. Previous to that, he held various positions in the research and development department of Pari GmbH. He is a graduate biomedical engineer and a certified senior project manager (IPMA® Level B) and is a member of The Aerosol Society, the European Respiratory Society (ERS) and the International Society for Aerosols in Medicine (ISAM).

​

​

​

​

David is the VP of Research at Insmed Incorporated, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, David worked at Aradigm (1996 to 2018) covering all phases of product development and led the development of preclinical research, CMC activities and intellectual property. Prior to joining Aradigm, David worked at Genentech, Inc. (1988 to 1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993.

David holds a chemical engineering degree from MIT (SB) and UC Davis (MS) and a pharmacy degree from the University of Sydney (PhD).

​

​

​

​

​

​

Anne Marie Healy is Professor of Pharmaceutics and Pharmaceutical Technology in the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Ireland. Anne Marie has a B.Sc. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of Dublin. She joined the School of Pharmacy, TCD in 1992 as a Lecturer in Pharmaceutics. In 2010 she was elected Fellow of Trinity College.

Professor Healy has published extensively, with over 120 international peer reviewed publications. She has graduated 22 PhD students and mentored 26 postdoctoral researchers. Her research interests include pharmaceutical material science, preformulation and formulation of pharmaceuticals, amorphous solids, co-crystals, formulating poorly soluble drugs, pharmaceutical processing and pulmonary drug delivery.

Anne Marie is a Co-Principal Investigator of the SSPC - the Science Foundation Ireland Research Centre for Pharmaceuticals (www.sspc.ie) and is one of the Co-Directors of the EPSRC-SFI Centre for Doctoral Training in Transformative Pharmaceutical Technologies (https://www.transpharmtech-dtc.ac.uk/).

Francesca Buttini is currently holding an Associate Professor position at the Food and Drug Department, University of Parma (IT) and where now she is leading the unit dedicated to design of pharmaceutical products for inhalation. In 2014, she was appointed as Visiting Lecturer at the Institute of Pharmaceutical Science of King’s

College London (UK). Combining her background in pharmaceutical technology, regulatory aspects, and device design, she is executing research programs aimed to deliver medicinal products that take into consideration the patient, industrial and regulatory requirements. Up to date, she has published more than 80 original papers

and as a result of her research achievement she obtained in 2017 the DDL Emerging Scientist Awards from the UK Aerosol Society. Francesca Buttini is a founder of

PlumeStars, an innovative SME, dedicated to development of orphan drug products to treat lung and systemic disease by inhalation therapy.

​

​

Patrick Goncalves, Account Executive, Business Development – Inhalation & Nasals, has over 8 years’ experience of pharmaceutical industry, with extensive expertise in Dry powder Inhalation. In his current role, he is responsible for growing the Inhalation & Nasal business in Europe. Patrick joined Catalent from Harro Höfliger where he held various sales and project management roles, and most recently was a Senior Sales Manager for Inhalation Technologies overseeing all dry powder inhalation projects. Patrick holds a Bachelor Industrial engineering from the University of Esslingen and an MBA in Sales Engineering from the University of Kaiserslautern.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Prof. Dr. Regina Scherließ (*1979) is a professor for Pharmaceutics and Biopharmaceutics, vice-dean for research of the Faculty of Natural Sciences at Kiel University (since 2022) and chair of the Department of Pharmaceutics at Kiel University, Germany. As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel

University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015). She also is member of the board of the research focus area KiNSIS (Kiel Nano Interface and Surface Sciences) at Kiel

University (since 2020). Her research interests include disperse systems and nanoparticles.  stabilization of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. She is a co-founder of the Nasal Research Focus Group, a research consortium from academia and industry

focusing on nasal drug delivery.

​

Figen Onuk Gören is a Pharma Professional and has more than 29 years of experience in the Pharmaceutical Industry in various roles in Research& Development, Technical Operations, Product Technology Transfer, Process Improvement, Lean Management, Quality, Toll Manufacturing, and Project&Budget Management. She executed and coordinated Research and Development studies for all dosage forms including nasal spray products as a generic, hybrid generic, and combination including patent application and bioequivalence studies and submission dossier preparation. Additionally, she executed and coordinated technology transfer studies for all dosage forms from the donor site to receiving site or to CMO. She managed lots of API source changes, process validation, cost reduction, problem-solving, and lean management studies. 

She is in the Board of Management of CRS ( Controlled Release Society) since August 2022. 

Figen holds a Bachelor Chemist degree from Trakya University and an MBA from İstanbul University and Pharmacology Master Degree from Marmara University.​

​

​

​

​

Tuncay is Senior Lecturer at the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne Australia. His research focuses on micro/nano mechanical systems and microfluidics.  He is leading the Dynamic Micro Devices Laboratory, which combines nanofabrication and acoustics to study the interaction of vibrating micro/nanoscale structures with the surrounding fluid media for aerosol delivery and synthesis of nanomaterials. He has 75+ peer reviewed papers and 8 patents. He was awarded his PhD in Engineering from Cornell University in Ithaca NY in 2007. Prior to joining Monash University, he worked as a postdoctoral researcher at Delft University of Technology in the Netherlands, and University College London in UK.  In 2015, he was a visiting scientist at the Paul Scherrer Institut in Switzerland.

​

​

​

​

Oliver Langer is Associate Professor at the Medical University of Vienna in Austria (Department of Clinical Pharmacology). He has studied pharmacy at the University of Vienna (Austria) and has received his PhD degree from the Karolinska Institute in Sweden. In his research, he uses preclinical and clinical positron emission tomography (PET) imaging to address different questions related to drug disposition. He has a special research interest in drug transporters and has developed several new PET protocols to visualize transporter activity in different organs (brain, lungs, eye, liver, kidneys).

​

​

​

​

​

​

​

​

Severin Mairinger is an translational imaging scientist at the Medical University of Vienna in Austria (Department of Clinical Pharmacology). He has studied biotechnology and received his PhD in molecular biology from the University of Vienna. He is a trained radiochemist and his research focuses on the evaluation of small molecules in preclinical and clinical positron emission tomography PET studies. His research interests include membrane transporter proteins at various tissue barriers.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Dr. Hasan Bayram received his MD degree from Erciyes University in 1988, and completed his Pulmonology Residency at Dicle University School of Medicine in 1999, Diyarbakır. He performed his PhD in the field of asthma and air pollution at Queen Mary University of London, UK (1994-1998), and worked as a Post-Doctoral Research Fellow at National Heart and Lung Institute (2002-2003), Imperial College, London. Later, he set up the Respiratory Research Laboratory at University of Gaziantep, and continued on his research studies from 2005 to 2016 at the same institution. He moved to School of Medicine, Koç University in 2016, where he continuous his work as a full-time professor in pulmonary medicine. Dr Bayram is author of more than 100 full papers and book chapters.

Dr Bayram’s main research areas include adverse health effect of air pollutants, particularly diesel exhaust particles, health effects of climate change including desertification, nanotoxicology, and allergen-particle interaction. His ongoing research includes mechanisms underlying pathogenesis of chronic obstructive pulmonary diseases (COPD) including role of progenitor/stem cells, circadian rhythm, ciliary activity of airway epithelial cells in COPD and primary ciliary dyskinesia and bronchiectasis. His recent studies have focused on effects of SARS-COV-2 on airway epithelial cells, and pollutant-SARS-CoV-2 interaction.

​

She is a Professor of Pulmonary Diseases at the Gazi University School of Medicine Department of Pulmonary Diseases, Ankara Turkey. After qualifying in medicine in 1994, she undertook clinical training (residency)

at the Gazi University School of Medicine Department of Pulmonary Diseases (1994- 2000). She has been working in the same department as an academic faculty and

consulting physician from that date. She had a professor’s degree in 2010. She had the Turkish Thoracic Society Young Investigator award in 2001. The same year she worked in Vrije University Hospital in Amsterdam for invasive bronchoscopic procedures with ERS short-term training fellowship. She is a member of the Turkish Thoracic Society, Turkish Society of Allergy and Clinical Immunology, European Respiratory Society, and American Thoracic Society. She is also a member of the GINA Assembly since 2017. She took part in the Turkish translation of the GINA Severe Asthma Guideline V2.0 in 2019 and GINA Turkish Pocket Guideline 2022. She has worked as a member and head of the Turkish Thoracic Society’s Executive Committee of the Asthma and Allergy Assembly and as Scientific Committee Chair of the Turkish Thoracic Society. She is one of the authors of the National Guideline of Asthma Diagnosis and Treatment. Currently, she is the chief editor of the Turkish Respiratory Journal. Her research and clinical interest are mainly focused on asthma and pulmonary thromboembolism.

Karadag was graduated from Istanbul Faculty of Medicine in 1992. He completed pediatric specialization training at Zeynep Kamil Gynecology and Children Hospital in 1997. In 1995 and 1996, he received the European Respiratory Society Training Fellowship Award and worked at

the Royal Brompton Hospital in London, UK. In 1997, he started to work in Marmara University Faculty of Medicine, Department of Pediatric Pulmonology. In 2005, upon receiving European Respiratory Society Research Fellowship, he carried out studies on epidemiology of asthma and allergic diseases at the Department of Pediatric Allergy at the University of Munich, Germany. Since 2011, he has been the Head of the Department of Pediatric Pulmonology at Marmara University. He is

currently a member of the Executive Committees at Turkish Pediatric Association, Turkish Pediatric Pulmonology Society and Marmara Pediatric Society. He is also a member of the European Respiratory Society Clinical Research Commission for Severe Asthma in Children, Bronchiectasis and Primary Ciliary Dyskinesia Guidance Commissions. In 2023, he has been elected as the Chair of the ERS Paediatric Cystic Fibrosis Working Group.

​

​

​

Yasemin Gokdemir have been working as Professor of Pediatric Pulmonology in

Marmara University, Istanbul. She is actively co-leading the Marmara University Cystic

Fibrosis (CF) Center, which is the largest in Turkey (with 435 CF patients). Besides CF,

she was also interested in pediatric lung transplantation, neuromuscular disease and

sleep.

She served as Head of the Turkish Thoracic Society (TTS) Pediatric Pulmonology

Assembly between 2020-2023. She has given lectures and training sessions for Middle

East CF Association (MECFA) for countries including Azerbaijan, Egypt, Jordan, Sudan,

Ethiopia and Algeria.

​

Dr Per Bäckman is senior adviser at Per Backman Consulting AB /Emmace AB. In this role, he provides advice to the pharmaceutical industry on biopharmaceutical aspects related to the development of orally inhaled and nasal drug products (OINDP). This includes general aspects related to the planning and execution of clinically relevant test programs as well as the application of physiologically-based biopharmaceutical modelling (PBBM) to understand the relation between in vitro drug performance attributes and clinical performance. Per holds a Ph.D. in physical chemistry from the University of Lund, Sweden and has 25 years of OINDP industry experience in various roles.

​

​

​

Deborah has extensive experience driving growth in medical research and life science markets.  She

joined Proveris Scientific in 2016 as European Sales Director with a focus on expanding the company’s

European customer base.  Deborah has a PhD in Chemistry from Kings College London specialising in

Biosensors for clinical applications and held postdoctoral research positions at KCL London and Oxford

University. Deborah has over 20 years’ experience in business development roles with life science

technology providers, including ADInstruments focusing on data acquisition and analysis in physiological

monitoring applications and Equivital in the wearable connected devices market.

Dr. Samuel Constant is co-founder and Chief Executive Officer of Epithelix (http://www.epithelix.com) a Swiss biotech company specialized in tissue engineering. Epithelix is a leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying

airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases, Bacterial and Viral infections. Samuel is in charge of global management and strategy the company.

Since 2006, Dr. Samuel Constant and his team have won 18 prizes for their scientific achievements,

technological innovation, and business development.

After graduating from ETH Zürich with a degree in Electrical Engineering in 1993, Mr. Taskent joined MIT for research and Polytechnic Institute of New York University for the Electrophysics and Technology MBA degrees. 

During 1998-2005, he worked as a R&D engineer, expert consultant and instructor at Lucent Technologies Bell Laboratories. During that timeframe he led major fiberoptic transmission system deployments.  During 2006-2007 worked as CTO at the Lucent Technologies Istanbul Office. 2008-2018 worked at Arkan & Ergin Corporate Finance, focusing startup valuation, development of Turkish startup ecosystem and growing the  technology transfer environment.  Since 2019 has been working at Atabay Pharmaceuticals and Fine Chemicals as director responsible for R&D and innovation.  Academically, teaching MBA students on technology and innovation management at Koç University since 2012. 

Currently serving as the Board Member at the University Industry Relationships Platforms, at the Swiss Chamber of Commerce in Turkey and at Izmir Biomedicine and Genome Center.

​

Danny Brinkley is a director in Teva's global respiratory and ophthalmic R&D division and is head of respiratory strategy and innovation. Danny has more than 25 years of experience working in respiratory development at companies that include GSK, Novartis and Teva. In his role at Teva, Danny has led generic CMC programs for pMDIs, DPIs and other novel dosage forms from concept to approval. As part of Danny's remit, he established and leads Teva's respiratory IVIVC department with a mission to achieve right-first-time bioequivalence studies and to improve the efficiency of regulatory approval.

​

​

​

​